Skip to main content
. 2022 May 20;13:849468. doi: 10.3389/fimmu.2022.849468

Table 4.

Patients’ side effects of chemotherapy for all patients according to programmed cell death ligand-1 (PD-L1).

n level Low PD-L1 High PD-L1 P
61 43
Decreased appetite (%) No 10 (16.4) 7 (16.3) 1.000
Yes 51 (83.6) 36 (83.7)
Nausea (%) No 7 (11.5) 4 (9.3) 0.975
Yes 54 (88.5) 39 (90.7)
Vomiting (%) No 32 (52.5) 18 (41.9) 0.386
Yes 29 (47.5) 25 (58.1)
Diarrhea (%) No 57 (93.4) 40 (93.0) 1.000
Yes 4 (6.6) 3 (7.0)
Mouth ulcers (%) No 60 (98.4) 42 (97.7) 1.000
Yes 1 (1.6) 1 (2.3)
Alopecia (%) No 29 (47.5) 19 (44.2) 0.890
Yes 32 (52.5) 24 (55.8)
Peripheral neurotoxicity (%) No 48 (78.7) 39 (90.7) 0.173
Yes 13 (21.3) 4 (9.3)
Anemia (%) Grade 0 34 (55.7) 21 (48.8) 0.621
Grade 1-2 27 (44.3) 22 (51.2)
Leukopenia (%) Grade 0 12 (19.7) 12 (27.9) 0.502
Grade 1-2 35 (57.4) 20 (46.5)
Grade 3-4 14 (23.0) 11 (25.6)
Neutropenia (%) Grade 0 8 (13.1) 12 (27.9) 0.157
Grade 1-2 25 (41.0) 16 (37.2)
Grade 3-4 28 (45.9) 15 (34.9)
Thrombocytopenia (%) Grade 0 49 (80.3) 30 (69.8) 0.313
Grade 1-2 12 (19.7) 13 (30.2)
Gastrointestinal reaction (%) Grade 0 7 (11.5) 5 (11.6) 0.701
Grade 1-2 53 (86.9) 38 (88.4)
Grade 3-4 1 (1.6) 0 (0.0)
Myelosuppression (%) Grade 0 5 (8.2) 10 (23.3) 0.096
Grade 1-2 20 (32.8) 11 (25.6)
Grade 3-4 36 (59.0) 22 (51.2)
Hepatic dysfunction (%) Grade 0 42 (68.9) 24 (55.8) 0.249
Grade 1-2 19 (31.1) 19 (44.2)